Target type: biologicalprocess
Any process that modulates the rate, frequency or extent of kidney development. Kidney development is the process whose specific outcome is the progression of the kidney over time, from its formation to the mature structure. The kidney is an organ that filters the blood and excretes the end products of body metabolism in the form of urine. [GOC:dph, GOC:tb, GOC:yaf]
Kidney development is a complex and tightly regulated process that involves a precise interplay of genetic and environmental factors. The development of the kidneys, which are responsible for filtering waste products from the blood and regulating electrolyte balance, begins early in embryonic life.
The process starts with the formation of the metanephric mesenchyme, a specialized tissue derived from the intermediate mesoderm. This mesenchyme interacts with the ureteric bud, an outgrowth from the Wolffian duct, initiating a series of reciprocal inductive events that drive kidney morphogenesis.
The ureteric bud undergoes branching morphogenesis, forming the collecting ducts and the renal pelvis. The metanephric mesenchyme responds to signals from the ureteric bud, condensing and differentiating into nephrons, the functional units of the kidney. Nephron formation involves a series of intricate steps, including the formation of the glomerulus, proximal tubule, loop of Henle, and distal tubule.
Multiple signaling pathways, including Wnt, FGF, BMP, and Shh, are crucial for regulating the different stages of kidney development. These pathways control cell proliferation, differentiation, and migration, ensuring the precise formation of the various structures within the kidney. Transcription factors, such as Pax2, Wt1, and Six2, are also essential for proper kidney development, playing critical roles in specifying cell fates and regulating gene expression.
The regulation of kidney development is highly sensitive to genetic mutations and environmental factors. Disruptions in these pathways can lead to various kidney diseases, including polycystic kidney disease, congenital anomalies of the kidney and urinary tract (CAKUT), and renal dysplasia.
Understanding the molecular mechanisms underlying kidney development is crucial for developing new therapeutic approaches for treating kidney diseases and for improving the success rates of kidney transplantation.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| Histone-lysine N-methyltransferase EZH2 | A histone-lysine N-methyltransferase EZH2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q15910] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| 3-deazaneplanocin | 3-deazaneplanocin: S-adenosylhomocysteine hydrolase antagonist | ||
| tanshinone | tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent | abietane diterpenoid | anticoronaviral agent |
| przewaquinone d | przewaquinone D: isolated from root of Salvia przewalskii; structure given in first source; RN given refers to the trans- isomer, przewaquinone D | ||
| tanshinone ii a | tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source | abietane diterpenoid | |
| s-adenosylhomocysteine | S-adenosyl-L-homocysteine : An organic sulfide that is the S-adenosyl derivative of L-homocysteine. S-Adenosylhomocysteine: 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions. | adenosines; amino acid zwitterion; homocysteine derivative; homocysteines; organic sulfide | cofactor; EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor; EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor; epitope; fundamental metabolite |
| epz005687 | EPZ005687: inhibits EZH2 protein; structure in first source | indazoles | |
| epz-6438 | tazemetostat: a histone methyltransferase EZH2 inhibitor with antineoplastic activity | ||
| gsk-2816126 | GSK-2816126: inhibits EZH2 methyltransferase; structure in first source | piperazines; pyridines | |
| gsk343 | GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM). GSK343: an EZH2 methyltransferase inhibitor | aminopyridine; indazoles; N-alkylpiperazine; N-arylpiperazine; pyridone; secondary carboxamide | antineoplastic agent; apoptosis inducer; EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor |
| 1-[(1R)-1-(1-ethylsulfonyl-4-piperidinyl)ethyl]-N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-3-indolecarboxamide | (R)-1-(1-(1-(ethylsulfonyl)piperidin-4-yl)ethyl)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1H-indole-3-carboxamide: EZH2 inhibitor | indolecarboxamide |